BSSP (Cantech Holding) ROCE %: 0.00% (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantech Holding ROCE %?

Cantech Holding BSSP -99.50% ROCE % is 0.00% as of Sep. 2015.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cantech Holding's annualized ROCE % for the quarter that ended in Sep. 2015 was 0.00%.

Cantech Holding  (OTCPK:BSSP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cantech Holding ROCE % Related Terms

Cantech Holding ROCE % Historical Data

* Premium members only.

The historical data trend for Cantech Holding's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantech Holding ROCE % Chart

Cantech Holding Annual Data
Trend Dec11 Dec12 Dec13 Dec14
ROCE %
-2,200.00 -2,800.00 0.00 0.00

Cantech Holding Quarterly Data
Sep10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cantech Holding ROCE % Calculation

Cantech Holding's annualized ROCE % for the fiscal year that ended in Dec. 2014 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2014 )  (A: Dec. 2013 )(A: Dec. 2014 )
=-0.342/( ( (0.002 - 0.116) + (0.057 - 0.371) )/ 2 )
=-0.342/( (-0.114+-0.314)/ 2 )
=-0.342/-0.214
=159.81 %

Cantech Holding's ROCE % of for the quarter that ended in Sep. 2015 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2015 )  (Q: Jun. 2015 )(Q: Sep. 2015 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2015 )  (Q: Jun. 2015 )(Q: Sep. 2015 )
=0.124/( ( (0.021 - 0.725) + (0.011 - 0.699) )/ 2 )
=0.124/( ( -0.704 + -0.688 )/ 2 )
=0.124/-0.696
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Cantech Holding (BSSP) has a ROCE % of 0.00% as of Sep. 2015.
Is Cantech Holding's ROCE % too high?
Cantech Holding's current ROCE % is 0.00%.
How does Cantech Holding's ROCE % compare to HSTC and NTRR?
Cantech Holding's ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Cantech Holding's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantech Holding stock overvalued right now?
Cantech Holding (BSSP) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cantech Holding (BSSP), the current ROCE % is 0.00% as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantech Holding Business Description

Address 120 W Pomona Avenue, Monrovia, CA, USA, 91016
Cantech Holding Inc is a development stage immunotherapeutic-based technology company. Principally, it is focused on commercialization of its proprietary proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsine Fraction (IPF) is a therapeutic platform technology that can be used to facilitate varieties of applications. The company's product consists of IMMUNE-THERAPEUTIC PROTEIN which is a therapeutic protein isolated from porsine pepsin and is irreversible, modified, and fractionated to the sequence IPF.